Close Menu

NEW YORK (GenomeWeb) – DxTerity Diagnostics announced on Tuesday that it has arranged to receive up to $7.5 million in term debt financing from SWK Funding, a subsidiary of SWK Holdings.

The firm said it will use the proceeds toward the commercialization of its DxDirect genomics testing platform and DxCollect MicroCollection Device (MCD).

The firm's proprietary chemistry, DxDirect, enables multiplexed genomic testing directly from the patient sample. The DxCollect MCD allows for the stabilization and transport of blood RNA collected from a finger or heel prick.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.